Advanced Search

Study Preview



Study Title and Description

The consumption of bread enriched with betaglucan reduces LDL-cholesterol and improves insulin resistance in patients with type 2 diabetes.



Key Questions Addressed
1 Is this a fiber intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title The consumption of bread enriched with betaglucan reduces LDL-cholesterol and improves insulin resistance in patients with type 2 diabetes.
Author Liatis S., Tsapogas P., Chala E., Dimosthenopoulos C., Kyriakopoulos K., Kapantais E., Katsilambros N.
Country First department of internal medicine, Athens university medical school and diabetes center, Laiko hospital, 11527 Athens, Greece. s.liatis@yahoo.com
Year 2009
Numbers Pubmed ID: 19230737

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber Database
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
Year of Publication 2009
  • Comments Comments (
    0
    ) |
Country of Publication Greece
  • Comments Comments (
    0
    ) |
What was the study design? Randomized Controlled Trial (parallel)
  • Comments Comments (
    0
    ) |
Was the study blinded? double blind
  • Comments Comments (
    0
    ) |
Study diet type Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
Level of feeding control for dietary intervention Food partially provided
  • Comments Comments (
    0
    ) |
Sample size 46
  • Comments Comments (
    0
    ) |
Is there a run-in period? No
  • Comments Comments (
    0
    ) |
Is there a washout period? No
  • Comments Comments (
    0
    ) |
Did the administered fiber dose change over the course of the study? No
  • Comments Comments (
    0
    ) |
What is the age of the population (categorical)? Adults (20+ Years)
  • Comments Comments (
    0
    ) |
Study population, mean age in years ~63.36
  • Comments Comments (
    0
    ) |
Study population, age range in years -
  • Comments Comments (
    0
    ) |
Study Population, mean BMI, kg/m2 ~28.3
  • Comments Comments (
    0
    ) |
Study population, BMI Range, kg/m2 -
  • Comments Comments (
    0
    ) |
Baseline health status Diabetes,LDL-C> or = 3.36 mmol/l
  • Comments Comments (
    0
    ) |
Gender (% male) ~56
  • Comments Comments (
    0
    ) |
Fiber 1-type Beta-Glucans
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1- dose 1 (g) 3
  • Comments Comments (
    0
    ) |
Fiber 1- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 1-Duration of intervention 3 weeks
  • Comments Comments (
    0
    ) |
Fiber 1-how was the fiber administered? Single Food
  • Comments Comments (
    0
    ) |
Fiber 2-type -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 2-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 3-type -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 3-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 4-type -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 4-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Comparator 1- what was the comparator used in the intervention? Control
  • Comments Comments (
    0
    ) |
Comparator 1-dose 0
  • Comments Comments (
    0
    ) |
Comparator 1-duration of comparator intervention 3 weeks
  • Comments Comments (
    0
    ) |
Comparator 1-how was the comparator administered to participants? Single Food
  • Comments Comments (
    0
    ) |
Comparator 2- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 2-dose -
  • Comments Comments (
    0
    ) |
Comparator 2-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 2-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 3- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 3-dose -
  • Comments Comments (
    0
    ) |
Comparator 3-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 3-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 4- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 4-dose -
  • Comments Comments (
    0
    ) |
Comparator 4-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 4-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.